BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cannavo A, Komici K, Bencivenga L, D'amico ML, Gambino G, Liccardo D, Ferrara N, Rengo G. GRK2 as a therapeutic target for heart failure. Expert Opin Ther Targets 2018;22:75-83. [PMID: 29166798 DOI: 10.1080/14728222.2018.1406925] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Xie Z, Yang X, Duan Y, Han J, Liao C. Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. J Med Chem 2021;64:1283-345. [PMID: 33481605 DOI: 10.1021/acs.jmedchem.0c01511] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
2 Balo T, Sapi A, Kiss A, Raimbaud E, Paysant J, Cattin M, Berger S, Kotschy A, Faucher N. Synthesis of thieno[2,3-c]pyridine derived GRK2 inhibitors. Monatsh Chem. [DOI: 10.1007/s00706-021-02889-2] [Reference Citation Analysis]
3 Soares ROS, Losada DM, Jordani MC, Évora P, Castro-E-Silva O. Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies. Int J Mol Sci 2019;20:E5034. [PMID: 31614478 DOI: 10.3390/ijms20205034] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 16.7] [Reference Citation Analysis]
4 Xu Z, Yan S, Wu H, Zhang Y, Wei W. Angiotensin II and tumor necrosis factor-α stimulate the growth, migration and invasion of BEL-7402 cells via down-regulation of GRK2 expression. Digestive and Liver Disease 2019;51:263-74. [DOI: 10.1016/j.dld.2018.06.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Altamish M, Samuel VP, Dahiya R, Singh Y, Deb PK, Bakshi HA, Tambuwala MM, Chellappan DK, Collet T, Dua K, Gupta G. Molecular signaling of G-protein-coupled receptor in chronic heart failure and associated complications. Drug Dev Res 2020;81:23-31. [PMID: 31785110 DOI: 10.1002/ddr.21627] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Abd Alla J, Quitterer U. The RAF Kinase Inhibitor Protein (RKIP): Good as Tumour Suppressor, Bad for the Heart. Cells 2022;11:654. [PMID: 35203304 DOI: 10.3390/cells11040654] [Reference Citation Analysis]
7 Penela P, Inserte J, Ramos P, Rodriguez-Sinovas A, Garcia-Dorado D, Mayor F Jr. Degradation of GRK2 and AKT is an early and detrimental event in myocardial ischemia/reperfusion. EBioMedicine 2019;48:605-18. [PMID: 31594751 DOI: 10.1016/j.ebiom.2019.09.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
8 Cannavo A. G Protein-Coupled Receptor and Their Kinases in Cell Biology and Disease. IJMS 2022;23:5501. [DOI: 10.3390/ijms23105501] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Rakib A, Eva TA, Sami SA, Mitra S, Nafiz IH, Das A, Tareq AM, Nainu F, Dhama K, Emran TB, Simal-Gandara J. Beta-Arrestins in the Treatment of Heart Failure Related to Hypertension: A Comprehensive Review. Pharmaceutics 2021;13:838. [PMID: 34198801 DOI: 10.3390/pharmaceutics13060838] [Reference Citation Analysis]
10 Sun X, Zhou M, Wen G, Huang Y, Wu J, Peng L, Jiang W, Yuan H, Lu Y, Cai J. Paroxetine Attenuates Cardiac Hypertrophy Via Blocking GRK2 and ADRB1 Interaction in Hypertension. J Am Heart Assoc 2021;10:e016364. [PMID: 33372534 DOI: 10.1161/JAHA.120.016364] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Klenke S, Engler A, Ecker D, Ochsenfarth C, Danowski N, Peters J, Siffert W, Frey UH. The GRK2 Promoter Is Regulated by Early-Growth Response Transcription Factor EGR-1. Basic Clin Pharmacol Toxicol 2018;123:660-9. [DOI: 10.1111/bcpt.13055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Komici K, Conti V, Davinelli S, Bencivenga L, Rengo G, Filippelli A, Ferrara N, Corbi G. Cardioprotective Effects of Dietary Phytochemicals on Oxidative Stress in Heart Failure by a Sex-Gender-Oriented Point of View. Oxid Med Cell Longev 2020;2020:2176728. [PMID: 31998434 DOI: 10.1155/2020/2176728] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
13 Penela P, Ribas C, Sánchez-Madrid F, Mayor F Jr. G protein-coupled receptor kinase 2 (GRK2) as a multifunctional signaling hub. Cell Mol Life Sci 2019;76:4423-46. [PMID: 31432234 DOI: 10.1007/s00018-019-03274-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
14 Ye W, Yang S, Zhang L, Deng Z, Li W, Zhang J, Zhang L, Yun Y, Chen AF, Cao D. Multistep virtual screening for rapid identification of G Protein-Coupled Receptors Kinase 2 inhibitors for heart failure treatment. Chemometrics and Intelligent Laboratory Systems 2019;185:32-40. [DOI: 10.1016/j.chemolab.2018.12.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Komici K, Bencivenga L, Paolillo S, Gargiulo P, Formisano R, Assante R, Nappi C, Marsico F, D'Antonio A, De Simini G, Cittadini A, Vitale DF, Cuocolo A, Filardi PP, Ferrara N, Rengo G. Impact of body mass index on cardiac adrenergic derangement in heart failure patients: a 123I-mIBG imaging study. Eur J Nucl Med Mol Imaging 2020;47:1713-21. [PMID: 31872281 DOI: 10.1007/s00259-019-04658-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
16 Fahad Ullah M, Bhat SH, Tariq M, Abuduhier FM. Clinical Significance of Enzymes in Disease and Diagnosis. In: Husain Q, Ullah MF, editors. Biocatalysis. Cham: Springer International Publishing; 2019. pp. 213-31. [DOI: 10.1007/978-3-030-25023-2_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Denfeld QE, Mudd JO, Hasan W, Gelow JM, Hiatt SO, Winters-Stone K, Lee CS. Exploring the relationship between β-adrenergic receptor kinase-1 and physical symptoms in heart failure. Heart Lung 2018;47:281-4. [PMID: 29803296 DOI: 10.1016/j.hrtlng.2018.05.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
18 Oyama J, Node K. Is GRK2 a new target for cardiovascular disease? Hypertens Res 2018;41:575-7. [DOI: 10.1038/s41440-018-0052-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Bencivenga L, Liccardo D, Napolitano C, Visaggi L, Rengo G, Leosco D. β-Adrenergic Receptor Signaling and Heart Failure: From Bench to Bedside. Heart Fail Clin 2019;15:409-19. [PMID: 31079699 DOI: 10.1016/j.hfc.2019.02.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
20 Correale M, Tricarico L, Fortunato M, Mazzeo P, Nodari S, Di Biase M, Brunetti ND. New Targets in Heart Failure Drug Therapy. Front Cardiovasc Med 2021;8:665797. [PMID: 34026873 DOI: 10.3389/fcvm.2021.665797] [Reference Citation Analysis]
21 Kowalska M, Nowaczyk J, Fijałkowski Ł, Nowaczyk A. Paroxetine-Overview of the Molecular Mechanisms of Action. Int J Mol Sci 2021;22:1662. [PMID: 33562229 DOI: 10.3390/ijms22041662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Marzano F, Rapacciuolo A, Ferrara N, Rengo G, Koch WJ, Cannavo A. Targeting GRK5 for Treating Chronic Degenerative Diseases. Int J Mol Sci 2021;22:1920. [PMID: 33671974 DOI: 10.3390/ijms22041920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Mucke HA. Patent highlights February-March 2021. Pharm Pat Anal 2021;10:183-90. [PMID: 34229448 DOI: 10.4155/ppa-2021-0010] [Reference Citation Analysis]
24 Bencivenga L, Palaia ME, Sepe I, Gambino G, Komici K, Cannavo A, Femminella GD, Rengo G. Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New Biomarker? Cells 2021;10:457. [PMID: 33669936 DOI: 10.3390/cells10020457] [Reference Citation Analysis]
25 Murga C, Arcones AC, Cruces-Sande M, Briones AM, Salaices M, Mayor F Jr. G Protein-Coupled Receptor Kinase 2 (GRK2) as a Potential Therapeutic Target in Cardiovascular and Metabolic Diseases. Front Pharmacol 2019;10:112. [PMID: 30837878 DOI: 10.3389/fphar.2019.00112] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
26 Wang Z, Zhang M, Xu Y, Gu Y, Song Y, Jiang T. Identification of Independent and Communal Differentially Expressed Genes as Well as Potential Therapeutic Targets in Ischemic Heart Failure and Non-Ischemic Heart Failure. Pharmgenomics Pers Med 2021;14:683-93. [PMID: 34163213 DOI: 10.2147/PGPM.S313621] [Reference Citation Analysis]
27 Arosio B, Corbi G, Davinelli S, Giordano V, Liccardo D, Rapacciuolo A, Cannavo A. Sex Differences in Cardiovascular Diseases: A Matter of Estrogens, Ceramides, and Sphingosine 1-Phosphate. Int J Mol Sci 2022;23:4009. [PMID: 35409368 DOI: 10.3390/ijms23074009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
28 Marzano F, Liccardo D, Elia A, Mucio I, de Lucia C, Lucchese AM, Gao E, Ferrara N, Rapacciuolo A, Paolocci N, Rengo G, Koch WJ, Cannavo A. Genetic Catalytic Inactivation of GRK5 Impairs Cardiac Function in Mice Via Dysregulated P53 Levels. JACC Basic Transl Sci 2022;7:366-80. [PMID: 35540100 DOI: 10.1016/j.jacbts.2022.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Nykamp MJ, Zorumski CF, Reiersen AM, Nicol GE, Cirrito J, Lenze EJ. Opportunities for Drug Repurposing of Serotonin Reuptake Inhibitors: Potential Uses in Inflammation, Infection, Cancer, Neuroprotection, and Alzheimer's Disease Prevention. Pharmacopsychiatry 2021. [PMID: 34875696 DOI: 10.1055/a-1686-9620] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Liccardo D, Cannavo A, Spagnuolo G, Ferrara N, Cittadini A, Rengo C, Rengo G. Periodontal Disease: A Risk Factor for Diabetes and Cardiovascular Disease. Int J Mol Sci. 2019;20. [PMID: 30897827 DOI: 10.3390/ijms20061414] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 20.3] [Reference Citation Analysis]
31 Chen H, Cai K. DSCAM-AS1 mediates pro-hypertrophy role of GRK2 in cardiac hypertrophy aggravation via absorbing miR-188-5p. In Vitro Cell Dev Biol Anim 2020;56:286-95. [PMID: 32377998 DOI: 10.1007/s11626-020-00441-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
32 Cannavo A, Marzano F, Elia A, Liccardo D, Bencivenga L, Gambino G, Perna C, Rapacciuolo A, Cittadini A, Ferrara N, Paolocci N, Koch WJ, Rengo G. Aldosterone Jeopardizes Myocardial Insulin and β-Adrenergic Receptor Signaling via G Protein-Coupled Receptor Kinase 2. Front Pharmacol 2019;10:888. [PMID: 31447681 DOI: 10.3389/fphar.2019.00888] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]